Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases
Latest Information Update: 21 Dec 2023
At a glance
- Drugs Bintrafusp alfa (Primary) ; Pimasertib (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Status changed from active, no longer recruiting to completed.
- 07 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2021 New trial record